President’s Pick – April 2023
Researchers involved in developing oligonucleotide therapeutics have always been known for picking difficult problems related to difficult diseases. SOD1-ALS is a deadly neurodegenerative disease caused by a mutation in the SOD1 protein. Because the disease is due to the SOD1 mutation, it is possible to ...
President’s Pick – March 27 2023
PMID: 36881759 DOI: 10.1093/nar/gkad067 Writing a good review article is not easy. A good Review not only summarizes the literature, it also provides an expert perspective so that the reader has enough insight to sort the important from the unimportant. That means that the expert authors, who ...
President’s Pick – March 2023
The journal RNA, the official publication of the RNA society, has always been one of my favorite journals. RNA’s April issue is devoted to Perspective articles related to nucleic acids therapeutics. Michelle Hastings and Adrian Krainer deserve our thanks as they took on the task ...
OTS President’s Pick Paper – October 2022
I would like to thank everyone who attended OTS 2022, whether in person or virtual. Special thanks to Keith Gagnon and Annemieke Aartsma-Rus and the entire organizing group for putting together such a great schedule of talks. Masad Damha coordinated the intricate network of award ...
OTS President’s Pick Paper – September 2022
Today’s President’s pick is a bit unusual. I was watching television and noticed a new commercial. A jolly man was happily proclaiming that he had a new medication for controlling his high cholesterol. He seemed very pleased. We’ve all seen these commercials many times before, ...
OTS President’s Pick Paper – July 2022
By: David Corey Establishing an environment in which rigorous scientific inquiry is practiced: A personal journey. Stanley Crooke Nucleic Acids Research, gkac526, https://doi.org/10.1093/nar/gkac526 Published: 08 July 2022. https://academic.oup.com/nar/advance-article/doi/10.1093/nar/gkac526/6633881?login=true The Story of Ionis Pharmaceuticals For those new to the field, Ionis Pharmaceuticals has always been ...
OTS President’s Paper Pick – June 2022
Successful nucleic acid therapeutic projects have one thing in common - rigor. Lack of controls has many consequences ranging from failed companies, seminars that waste the time of all involved, and lost hopes of patients. In this “President’s Pick”, Past President Annemieke Aartsma-Rus lays ...
President’s Pick of Presentations from the Annual OTS Meeting
By: Annemieke Aartsma-Rus, Ph.D. The second virtual annual meeting of the Oligonucleotide Therapeutics Society (OTS) took place September 26-29 on a computer or laptop near you. Despite the challenges the pandemic poses on research and development in general, the oligonucleotide therapy field has made ...
OTS President’s Paper Pick – August 2021
By: Annemieke Aartsma-Rus, Ph.D. The paper information: CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis Julian D Gillmore, Ed Gane, Jorg Taube, Justin Kao, Marianna Fontana, Michael L Maitland, Jessica Seitzer, Daniel O’Connell, Kathryn R Walsh, Kristy Wood, Jonathan Phillips, Yuanxin Xu, Adam Amaral, Adam ...
OTS President’s Paper Pick– July 2021
By: Annemieke Aartsma-Rus, Ph.D. Safety, Immunogenicity, and Efficacy of the BNT162b2 Covid-19 Vaccine in Adolescents. Frenck et al. N Engl J Med. 2021 May 27; DOI: 10.1056/NEJMoa2107456 While waiting in line to receive my second Moderna Covid-19 mRNA vaccine, I read the recent paper on ...
